The optimal neoadjuvant regimen for nonsmall cell lung cancer
A meta-analysis
Yi Liu, MSa, Chong Zhao, MSb, Qiuliang Lu, MSa, Yirong Hu, MSa,*

Abstract
Objective: To compare the efficacy and complications of different neoadjuvant to determine the optimal regimens for nonsmall cell lung cancer (NSCLC) patients.

Methods: A systematic search of the Web of Science, and PubMed databases was conducted through June 3, 2021, reporting a comparison of chemotherapy, chemoradiotherapy, and immunotherapy.

Results: Of 3462 studies, 25 were considered for evidence synthesis. 1035 patients who received chemoradiotherapy or radiotherapy before surgery did not prolong the overall survival (OS) compared with 1038 patients who received surgery alone (hazard ratio [HR] 1.13, 95% CI 1:00–1:28, P = 0:05). 1192 patients received chemoradiotherapy and 864 patients received chemotherapy or radiotherapy; chemoradiotherapy prolonged the OS compared with chemotherapy (HR 0.52, 95% CI 0:29 to 0.95, P = .03). Compared with 110 patients who received other therapy, 93 patients who received immunotherapy had prolonged the OS (HR 1.56, 95% CI 1:08–2:25, P = .02). Chemoradiotherapy increased the pathological response rate (HR 1.68, 95% CI 1:33–2:12, P < .0001), and grade 3 and 4 adverse effects were not increased (HR 5.90, 95% CI 0.88 to 39.60, P = .007). Immunotherapy increased the pathological response (HR 2.79, 95% CI 1:71–4.54, P < .0001), with no significant effects on grades 3 and 4 adverse (HR 0.71, 95% CI 0:19–2:64, P = .61).

Conclusion: Our data showed that chemotherapy may prolong OS and PFS, but not statistically significant; however, the combination of chemotherapy and radiation did show an advantage, and immunotherapy may be also the choice for neoadjuvant therapy.

Abbreviations: CI = confidence interval, GVP = gemcitabine–vinorelbine–cisplatin, HR = hazard ratio, MIP = mitomycin–ifosfamide–cisplatin, NSCLC = non-small cell lung cancer, OR = odds ratio, OS = overall survival, PFS = progression-free survival

Keywords: complications, meta-analysis, neoadjuvant, non-small cell lung cancer, overall survival

1. Introduction
Almost one-quarter of all cancer deaths are due to lung cancer, and 5-year relative survival rates are merely 21% for all stages combined.[1] More than 80% of patients affected by nonsmall cell lung cancer (NSCLC), early-stage lung cancer can be treated by innovative imaging-guided resection, minimally invasive approach, or multiple approaches with very good short-term outcomes, enhanced recovery, and prolonged overall survival.[2] As symptoms present late in the disease, the majority of patients (approximately 70%) already suffer from the locally advanced or metastatic disease at diagnosis and have an extremely limited possibility of being cured.[3] Neoadjuvant therapy has acceptable treatment-related toxicity and adverse event profile, it increases the likelihood of achieving an R0 resection and a pathological complete response for cancer therapy, including gastric cancer, breast cancer, etc.[4,5] Innovative systemic treatments and perioperative medical care have changed the role of surgery in the treatment of lung cancer. Treatments such as radiotherapy, chemotherapy, molecular targeted therapies, immunotherapy, and a combination of chemotherapy and radiotherapy are optional and performed depending on the histological type, pathological

Role of the funding source: None.

Informed consent: Informed consent was obtained from all individual participants in the included studies. For this study, formal consent was not required.

Conflict of Interest Statement: All named authors have no conflicts of interest to declare.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical approval: All procedures performed in the included studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards. This article does not contain any studies with human participants performed by any of the authors.

* Department of Thoracic Surgery, The People’s Hospital of Yichun City, Jiangxi, 336028, China, a Department of Respiratory, The People’s Hospital of Yichun City, Jiangxi, 336028, China, b Department of Neurology, The People’s Hospital of Yichun City, Jiangxi, 336028, China, c Department of Respiratory, The People’s Hospital of Yichun City, Jiangxi, 336028, China.

*Correspondence: Yirong Hu, No 88, Zhongshan Western Road, Yichun, Jiangxi 336028, China (e-mail: 24282894@qq.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Liu Y, Zhao C, Lu Q, Hu Y. The optimal neoadjuvant regimen for nonsmall cell lung cancer: a meta-analysis. Medicine 2022;101:34(e30159).

Received: 29 January 2022 / Received in final form: 30 June 2022 / Accepted: 6 July 2022
http://dx.doi.org/10.1097/MD.0000000000030159

http://dx.doi.org/10.1097/MD.0000000000030159
stage, presence of gene mutations, and overall condition of the patient.\cite{3,6–8} Herbs or their derivatives were also found to exert antiproliferation and potential antineoplastic activity\cite{9,10}; however, the genotoxicity, mutagenicity, and mechanisms on cancer cells needed more in-depth research.\cite{11–13} These treatment strategies have been widely adopted for neoadjuvant therapies and can markedly improve the prognosis of patients with the various stage of lung cancer.\cite{14–16} Neoadjuvant therapy aims to shrink the tumor size and increase the success rate of the surgery treatment.

However, the optimal neoadjuvant regimen for locally advanced resectable NSCLC remains controversial. Previous studies indicated preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC, but toxic effects could not be assessed.\cite{17} Neoadjuvant radiotherapy alone does not improve resectability or survival, radiotherapy and chemotherapy combined are used for patients, the meta-analysis showed that chemoradiotherapy significantly increased the pathological complete response in mediastinal lymph nodes,\cite{18} study suggests that hyperfractionated accelerated radiotherapy in combination with chemotherapy is an effective strategy to treat patients with locally advanced lung cancer with the advantage of a smaller dose and shorter duration,\cite{19} on the other hand, a study showed that combination may increase the adverse effect.\cite{20} Recently, immune-oncology drugs have proven their efficacy in the treatment of NSCLC, numerous clinical trials are underway to investigate the efficacy of neoadjuvant immunotherapy in resectable NSCLC, and to compare these approaches with placebo or other treatments.\cite{3,14,21} Here, we performed a meta-analysis to explore the optimal neoadjuvant regimen for NSCLC.

2. Materials and Methods

2.1. Search strategy

We performed this meta-analysis by searching Web of Science, PubMed, and EMBASE databases for studies published through June 3, 2021. Additional records were identified by screening the reference in the identified studies. The search term was “non-small cell lung cancer neoadjuvant.”

2.2. Inclusion and exclusion criteria

Two investigators independently screened the data, and when different opinions occurred, an agreement was reached by discussion. The inclusion criteria were the followings: (1) comparing different neoadjuvant regimens; (2) nonsmall cell lung cancer was pathologically confirmed; (3) sufficient data that were reported or could be calculated. Major exclusion criteria were (1) incomplete data for analysis; (2) books and documents, meeting abstracts, comments, meta-analysis, reviews, and articles cannot extract sufficient data; (3) adjuvant but not neoadjuvant therapy; (4) small cell lung cancer; (5) gray literature; (6) papers written in other languages that cannot be translated into English; and (7) duplicate data.

---

**Figure 1.** Flow diagram of the details of the study.
Table 1
Summary of included studies.

| Study          | Year | Nation     | Prescription                                                      | Study          | Year | Nation     | Prescription                                                      |
|----------------|------|------------|-------------------------------------------------------------------|----------------|------|------------|-------------------------------------------------------------------|----------------|------|------------|-------------------------------------------------------------------|
| Zhao, X        | 2016 | China      | Antiangiogenic therapy and chemotherapy                          | Ratto, G. B    | 2011 | Europe     | Leukapheresis and chemotherapy                                  | Howardi, W     | 2006 | Egypt      | Radiotherapy                                                   |
| Ratto, G. B    | 2011 | Europe     | Chemoradiotherapy                                                | Girard, N      | 2010 | France     | Chemoradiotherapy                                                | Harzallah, S   | 2005 | Switzerland| Radiochemotherapy                                             |
| Girard, N      | 2010 | France     | Chemoradiotherapy                                                | Hamouda, W     | 2007 | Egypt      | Radiotherapy                                                      | Pezetta, E     | 2005 | Switzerland| Radiochemotherapy                                             |
| Hamouda, W     | 2007 | Egypt      | Radiotherapy                                                      | Harzallah, S   | 2005 | Switzerland| Radiochemotherapy                                             | Kumar, R       | 2020 | India      | Chemotherapy and hyper-fractionated accelerated radiation therapy|
| Harzallah, S   | 2005 | Switzerland| Radiochemotherapy                                             | Girard, N      | 2010 | France     | Chemoradiotherapy                                                | Zhao, X        | 2016 | China      | Antiangiogenic therapy and chemotherapy                          |
| Kumar, R       | 2020 | India      | Chemotherapy and hyper-fractionated accelerated radiation therapy| Girard, N      | 2010 | France     | Chemoradiotherapy                                                | Ratto, G. B    | 2011 | Europe     | Leukapheresis and chemotherapy                                  |
| Xiong, L       | 2020 | China      | Erlotinib                                                         | Hamouda, W     | 2007 | Egypt      | Radiotherapy                                                      | Howardi, W     | 2006 | Switzerland| Radiochemotherapy                                             |
| Altorki, N. K  | 2021 | USA        | Durvalumab plus radiotherapy                                     | Zhong, W. Z    | 2019 | China      | Erlotinib                                                         | Berghmans, T   | 2012 | Europe     | Gemcitabine-vinorelbine-cisplatin                                |
| Zhong, W. Z    | 2019 | China      | Erlotinib                                                         | Berghmans, T   | 2012 | Europe     | Gemcitabine-vinorelbine-cisplatin                                | Cascone, T     | 2020 | USA        | Nivolumab plus ipilimumab                                      |
| Berghmans, T   | 2012 | Europe     | Gemcitabine-vinorelbine-cisplatin                                | Chen, W. Q     | 2018 | China      | Erlotinib                                                         | Chen, W. Q     | 2018 | China      | Erlotinib                                                        |
| Cascone, T     | 2020 | USA        | Nivolumab plus ipilimumab                                       | Scagliotti, G. V| 2012 | Europe     | Chemotherapy                                                     | Pisters, K. M  | 2010 | USA        | Chemotherapy                                                    |
| Chen, W. Q     | 2018 | China      | Erlotinib                                                         | Scagliotti, G. V| 2012 | Europe     | Chemotherapy                                                     | Gilligan, D.   | 2007 | Europe     | Chemotherapy                                                    |
| Roth, M        | 1994 | USA        | Chemotherapy                                                     | Pisters, K. M  | 2010 | USA        | Chemotherapy                                                     | Gilligan, D.   | 2007 | Europe     | Chemotherapy                                                    |
| Roselli, M     | 1994 | Spain      | Chemotherapy                                                     | Pless, M       | 2015 | Europe     | Chemoradiotherapy                                                | Thomas, M      | 2008 | Germany    | Chemoradiotherapy                                                |
| Depierre, M    | 2002 | France     | Chemotherapy                                                     | Pless, M       | 2015 | Europe     | Chemoradiotherapy                                                | Toyooka, S     | 2012 | Japan      | Chemoradiotherapy                                                |
| Nagai, T       | 2003 | Japan      | Chemotherapy                                                     | Toyooka, S     | 2012 | Japan      | Chemoradiotherapy                                                | Katakami, N    | 2012 | Japan      | Chemoradiotherapy                                                |
| Fell, M        | 2010 | Europe     | Chemotherapy                                                     | Katakami, N    | 2012 | Japan      | Chemoradiotherapy                                                | Yang, C. F     | 2015 | USA        | Chemoradiotherapy                                                |
| Yang, C. F     | 2015 | USA        | Chemoradiotherapy                                                | Roth, M        | 1994 | USA        | Chemotherapy                                                     | Roth, M        | 1994 | USA        | Chemotherapy                                                     |
| Roth, M        | 1994 | USA        | Chemotherapy                                                     | Roselli, M     | 1994 | Spain      | Chemotherapy                                                     | Roselli, M     | 1994 | Spain      | Chemotherapy                                                     |

OS = overall survival, PFS = progression-free survival.
2.3. Data extraction

Overall survival (OS), response rate, and complications were the main indices to evaluate the treatments. Authors’ names, publication year, patient number, neoadjuvant regimen, and complications were collected from the included studies. Complications included leucopenia, anemia, thrombocytopenia, nausea/vomiting, diarrhea, alopecia, elevated aminotransferase, and elevated total bilirubin. Clavien–Dindo Grading System was used to classify the complications. We divided the complications into the minor and severe groups, the minor group included Clavien–Dindo grade I and II, and the severe group include grades III, IV, and V. There was no Clavien–Dindo grade V complication in all patients.

2.4. Statistical analysis

All data were entered into Review Manager Software (The Cochrane Collaboration, version 5.3). Odds ratio (OR) with 95% confidence interval (CI) were analyzed. Statistical heterogeneity among studies was evaluated utilizing I² statistics and P values. When P < 0.05 indicated homogeneity among studies, the fixed effects model method was applied. When I² ≥ 50%, the random-effects model was used. Publication bias was assessed using a funnel figure. A sensitivity analysis was performed to assess the stability of the results. The statistical analysis was performed using Review Manager Software (The Cochrane Collaboration, version 5.3).

3. Results

3.1. Study selection and characteristics

A total of 3462 records were identified through datasets, 1020 records were excluded after initial analysis and further screening was performed. Finally, 25 research were included in this meta-analysis [14,22–43] (Fig. 1). Of these studies, 7 focus on immunotherapy,[14,23,24,34,40,43,43] 8 focus on chemoradiotherapy,[19,20,29,31,33,38,39,41] 5 focus on chemotherapy or radiotherapy.[22,27,28,32,37] Include patients varied from ten to hundreds, all the studies were recorded in the 21st century (Table 1). We compared the effectiveness of different treatments for neoadjuvant, overall survival, response rate, and complications were evaluated.

3.2. Chemotherapy or radiotherapy

Nine studies assessed the results of overall survival[22,25–27,30,32,35–37] of 1035 patients who received chemotherapy or radiotherapy before surgery did not prolong the OS compared with 1038 patients who received surgery alone (hazard ratio [HR] 1.13, 95% CI 1.00–1.28, P = 0.05, Fig. 2A). However, chemotherapy did contribute to progression-free survival (PFS, HR 1.13, 95% CI 1.04–1.36, P = 0.01, Fig. 2B). The pathological response was about 22–63%, Hamouda, W, etc[41] compared the radiotherapy and chemotherapy, no significant difference was found between the 2 groups (HR 0.40, 95% CI 0.14–1.18, P = 0.10), Berghmans, T, etc[22] compared to 2 neoadjuvant chemotherapy (gemcitabine–vinorelbine–cisplatin, GVP VS mitomycin–ifosfamide–cisplatin, MIP), objective response rates to induction CT were 65% (GVP) and 60% (MIP) (P = 0.55), while GVP was associated with more hematological toxicity, mainly thrombopenia (P = 0.03). Scagliotti, G, V, etc[37] also found chemotherapy increased the grade 3 or 4 adverse (HR 5.59, 95% CI 2.94 to 10.63, P < 0.0001).

3.3. Chemoradiotherapy

As shown in Figure 3, 1192 patients received chemoradiotherapy and 864 patients received chemotherapy or radiotherapy, chemoradiotherapy prolonged the OS compared with chemotherapy (HR 0.52, 95% CI 0.29 to 0.95, P = 0.03, Fig. 3A), PFS was also found a significant difference between chemoradiotherapy and chemotherapy (HR 0.58, 95% CI 0.37 to 0.92, P = 0.02, Fig. 3B). Chemoradiotherapy increased the response rate by 68% (HR 1.68, 95% CI 1.33–2.12, P < 0.0001, Fig. 3C), and grade 3 and 4 adverse effects were no difference between the 2 groups (HR 5.90, 95% CI 0.88 to 39.60, P = 0.07, Fig. 3D).

3.4. Immunotherapy

Compared with other therapy, 93 patients who received immunotherapy did prolong the OS (HR 1.56, 95% CI 1.08–2.23, P = 0.02, Fig. 4A), 1 study indicated immunotherapy was a benefit for PFS (HR 0.39, 95% CI 0.24–0.64, P = 0.0002, Fig. 4B). Immunotherapy increased the pathological response by 2.79 folds (HR 2.79, 95% CI 1.71–4.54, P < 0.0001, Fig. 4C), with no significant effects on grade 3 and 4 adverse (HR 0.71, 95% CI 0.19–2.64, P = 0.61, Fig. 4D).

Figure 2. Forest plot for overall survival (A) and progression-free survival (B) for chemotherapy neoadjuvant comparing surgery alone.
3.5. Publication bias

Funnel figures were used to evaluate the publication bias for OS, no obvious bias was found as the figure was fundamental symmetry in the chemotherapy or radiotherapy group (Fig. 5A), chemoradiotherapy group (Fig. 5B), and immunotherapy group (Fig. 5C).

4. Discussion

Our meta-analysis summarizes the efficacy and safety outcomes of the currently published trials. A comprehensive search and systematic analysis of adjuvant therapy for nonsmall cell lung cancer were conducted in this paper. Results indicated that the neoadjuvant matter chemotherapy, radiotherapy, chemoradiotherapy, or immunotherapy did not alter the OS, PFS was benefited from neoadjuvant in the immunotherapy group, but it was noted only 1 study investigated the PFS in this group, the sample size was small, data showed chemoradiotherapy and immunotherapy were contributing to the pathological response (Figs. 3C and 4C), which may reduce tumor stage and increase the chance of complete resection, on the other hand, we found the sever complications were associated with chemoradiotherapy (Fig. 3D). The choice of treatment requires a trade-off between survival benefits and the risk of complications.

Previous studies showed that the use of neoadjuvant chemotherapy before surgery could give additional benefits for NSCLC patients with mediastinal involvement compared to surgery alone, however, the survival benefit after long-term follow-up was not observed, some other studies supported chemotherapy offered a significant 5-year overall survival advantage, we noted that there are a variety of chemotherapy options, gemcitabine-cisplatin, paclitaxel-carcmboplatin, gemcitabine-vinorelbine-cisplatin, mitomycin-ifosfamide-cisplatin, etc were optional, these regimens were mainly platinum-based chemotherapy. Both gemcitabine-vinorelbine-cisplatin (GVP) and mitomycin-ifosfamide-cisplatin (MIP) neoadjuvant chemotherapy regimens shared similar efficacy in patients with NSCLC, costs were significantly higher for GVP regimens. The advantages of neoadjuvant chemotherapy may be limited due to the progress of anesthesia and surgery, 2 of...
included studies indicated neoadjuvant chemotherapy favored better OS, and 1 suggested perioperative chemotherapy consisted of cyclophosphamide (500 mg per square meter of the body-surface area given intravenously on day 1), etoposide (100 mg per square meter of the body-surface area given intravenously on days 1, 2, and 3), and cisplatin (100 mg per square meter of the body-surface area given intravenously on day 1), the other suggested 3 cycles of gemcitabine 1250 mg per square meter of the body-surface area on days 1 and 8 every 3 weeks plus cisplatin 75 mg per square meter of the body-surface area on day 1 every 3 weeks. Docetaxel plus cisplatin with concurrent radiation at a dose of 40 to 46 Gy used for induction chemoradiotherapy was verified by Toyooka, S, et al that it could prolong patients' overall survival and disease-free survival than the chemotherapy group (OS, \( P = .0020 \); PFS, \( P = .015 \)).

Our data indicated immunotherapy favored better OS and PFS than chemotherapy (Figs. 4A and 4B), the response rate was also higher in the immunotherapy group (Fig. 4C), and the adverse effect was not increased (Fig. 4D). Over the last decade, there has been an acceleration in the emergence of new inhibitors approved in NSCLC immunotherapy, since the first epidermal growth factor receptor inhibitor developed in 1990, dozens of new drugs have been developed. Nowadays, ipilimumab, nivolumab, and erlotinib were commonly applied in the clinic, data showed immunotherapy alone may be sufficient for neoadjuvant.

Studies have focused on the combined application of radiotherapy and chemotherapy, however, the pooled results were not satisfactory (Fig. 3A, B). The advent of novel irradiation techniques, such as 3-dimensional conformal radiation therapy (3D-CRT), intensity-modulated RT (IMRT), and volumetric-modulated arc therapy (VMAT), may improve clinical outcomes in some situations, our meta-analysis indicated clinical response was better in chemoradiotherapy, meanwhile, adverse effects were more common (Figs. 3C and 3D). Docetaxel plus cisplatin with concurrent radiation at a dose of 40 to 46 Gy used for induction chemoradiotherapy was verified by Toyooka, S, et al that it could prolong patients' overall survival and disease-free survival than the chemotherapy group (OS, \( P = .0020 \); PFS, \( P = .015 \)).

Our data indicated immunotherapy favored better OS and PFS than chemotherapy (Figs. 4A and 4B), the response rate was also higher in the immunotherapy group (Fig. 4C), and the adverse effect was not increased (Fig. 4D). Over the last decade, there has been an acceleration in the emergence of new inhibitors approved in NSCLC immunotherapy, since the first epidermal growth factor receptor inhibitor developed in 1990, dozens of new drugs have been developed. Nowadays, ipilimumab, nivolumab, and erlotinib were commonly applied in the clinic, data showed immunotherapy alone may be sufficient for neoadjuvant.

Carcinogenesis is initiated when an irreversible and heritable mutation occurs in one of the key proteins that control many vital cell functions, various genes such as MET, NTRK, ROS1, ALK, etc. were potential oncogenes, and drugs aimed to inhibit the activity of these genes were developed, individual immunotherapy will be possible soon.

Figure 4. Forest plot for overall survival (A), progression-free survival (B), pathological response rate (C), and grade 3-4 adverse (D) for neoadjuvant immunotherapy comparing chemotherapy or radiation.
Figure 5. Funnel plots evaluating possible publication bias.

Figure 6. The pathological responses and adverse effects were indicated, the pathological response was about 22–65% for the radiotherapy or chemotherapy, chemoradiotherapy increased the response rate by 1.68 folds, and immunotherapy increased the pathological response by 2.79 folds. III–IV adverse effects occurred in 15/58 in the radiotherapy or chemotherapy group, 30/58 in the chemoradiotherapy group, and 17/160 in the immunotherapy group.
Several limitations should be noted in this meta-analysis. First, subgroup analysis was not performed, neoadjuvant may exert different effect in distinct stage NSCLC, the role of neoadjuvant may be more vital for stage III NSCLC than stage I NSCLC; Second, studies from different country may achieved various results, racial and regional differences may lead to different efficacy of neoadjuvant; Third, differences in surgical techniques may lead to differences in patient survival, and advances in surgical techniques may vary in the selection of surgical patients; Fourth, NSCLC consist of squamous cell carcinoma, adenocarcinoma, and large cell lung cancer, this study did not focus on the response of different pathological types of lung cancer to neoadjuvant therapy; Fifth, adjuvant was applied for some patients, this study did not investigate the effect of adjuvant therapy on outcome; Sixth, the effect of neoadjuvant therapy on surgery-related data and complications was not analyzed; Seventh, the sample size of some studies is too small, the reliability of pooled results may be affected. Despite these shortcomings, this study is the most systematic meta-analysis to date, and we look forward to the results of more high-level clinical trials for further analysis.

5. Conclusion
In conclusion, our data showed the combination of chemotherapy and radiation show an advantage for prolonging OS and PFS, immunotherapy may be the best choice for neoadjuvant (Fig. 6).

Author contributions
Project development: Yirong Hu; data collection or management: Yi Liu and Yi Liu; data analysis and interpretation: Yi Liu and Chong Zhao; manuscript writing: Yi Liu and Chong Zhao; manuscript editing: Qiliang Lu; and study supervision: Yirong Hu.

References
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
[2] Montague F, Gassier F, Verussac N, et al. The role of surgery in lung cancer treatment: present indications and future perspectives—state of the art. Cancers. 2021;13:3711.
[3] Xiong L, Lou Y, Bai H, et al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. J Int Med Res. 2020;48:300060519887275.
[4] Rizzo A, Cusmai A, Massafra R, et al. Pathological complete response to neoadjuvant cheemoimmunotherapy for early-stage non-small breast cancer: an updated meta-analysis. Cells. 2022;11:1857.
[5] Yeh JH, Yeh YS, Tsai HL, et al. Neoadjuvant chemoradiotherapy for locally advanced gastric cancer: where are we at? Cancers (Basel). 2022;14:3026.
[6] Kong F, Wang Z, Liao D, et al. Non-small cell lung cancer: challenge and improvement of immune drug resistance. Front Oncol. 2021;11:739191.
[7] Rodak O, Peris-Díaz MD, Olbrromski M, et al. Current landscape of non-small cell lung cancer: epidemiology, historical classification, targeted therapies, and immunotherapy. Cancers. 2021;13:4705.
[8] Zhou Y, He M, Li R, et al. The safety and effectiveness of bevaciuzumab in the treatment of nonsquamous non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Biomed Res Int. 2021;2021:1–10.
[9] Galucio NCDR, Moyssés DDA, Pina JRS, et al. Antiproliferative, genotoxic activities and quantification of extracts and curcumin B obtained from Luffa operculata (L.) Cogn. Pharm Biol. 2013;51:1249–55.
[10] Neto R, Santos CBR, Henriques SVG, et al. Novel chalcones derivatives with potential antineoplastic activity investigated by docking and molecular dynamics simulations. J Biomol Struct Dyn. 2020;40:2204–16.
[11] Castro ALG, Cruz JN, Sodré DF, et al. Evaluation of the genotoxicity and mutagenicity of isoeleutherin and eleutherin isolated from Eleutherine pilcata herb, using bioassays and in silico approaches. Arabian J Chem. 2021;14.
[12] Neves GJ, Da CKS, de Carvalho TAA, et al. Measuring the structural impact of mutations on cytokine P450 21A2, the major steroid 21-hydroxylase related to congenital adrenal hyperplasia. J Biomol Struct Dyn. 2020;38:1425–34.
[13] Souza DSJO, de Jesus PFC, Barbosa DMAA, et al. In silico analyses of toxicity of the major constituents of essential oils from two Ipomoea L. species. Toxicom. 2021;195:111–8.
[14] Altoroki NK, McGraw TE, Boczkuk AG, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22:824–35.
[15] Eichhorn F, Klotz IV, Kriegsmann M, et al. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience. Lung Cancer. 2021;153:150–7.
[16] Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413–22.
[17] NSCLC Meta-analysis Collaborative Group. Preoperative chemotheraphy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–71.
[18] Ren S, Xu A, Lin Y, et al. A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. Transl Lung Cancer Res. 2021;10:3264–75.
[19] Kumar R, Kumar HS, Paramanandhan M, et al. Neoadjuvant chemo-immunotherapy followed by either continuous hyper-fractionated accelerated radiotherapy therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-a randomised prospective single institute study. J Cancer Res Ther. 2020;16:860–6.
[20] Girard N, Mornex F, Douillard JY, et al. Is neoadjuvant chemoradiation therapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFC-T-0101 phase II trial. Lung Cancer. 2010;69:86–93.
[21] Ulas EB, Dickhoff C, Schneider FL, et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6:100244.
[22] Berghmans T, Lafitte JJ, Giner V, et al. Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working Party. Lung Cancer. 2012;77:605–10.
[23] Casccone T, William WJ, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504–14.
[24] Chen WQ, Li P, Wang Q, et al. [A randomized controlled study of enalapril versus permiether combined with cisplatin in neoadjuvant chemotherapy of stage IIIA EGFMR-mutant lung adenocarcinoma], Zhonghua Zhong Liu Za Zhi. 2018;40:133–7.
[25] Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotheraphy followed by surgery compared with primary surgery in resectable stage I (except T1NO), II, and IIIA non-small-cell lung cancer. J Clin Oncol. 2002;20:247–53.
[26] Felip E, Rosell R, Maestra JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138–45.
[27] Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/PORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–37.
[28] Hamouda W, Dorgaham Y, Yosry A, et al. Neoadjuvant chemotheraphy in locally advanced non-small cell lung cancer. Gulf J Oncolog. 2007;55:64.
[29] Katakami N, Tada H, Mitsudomi T, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012;118:6126–35.
[30] Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIB N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003;125:54–60.
[31] Pezzetta E, Stupp R, Zouhair A, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg. 2005;27:1092–8.
[32] Pisters KM, Vallieres E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;28:1843–9.

[33] Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386:1049–56.

[34] Ratto GB, Costa R, Maineri P, et al. Neo-adjuvant chemosimmunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase III pilot study. Int J Immunopathol Pharmacol. 2011;24:1005–16.

[35] Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–8.

[36] Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.

[37] Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–8.

[38] Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636–48.

[39] Toyooka S, Kiura K, Shien K, et al. Induction chemoradiation is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954–60.

[40] Xiong L, Lou Y, Bai H, et al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. J Int Med Res. 2020;48:3000605198987275.

[41] Yang CF, Gulack BC, Gu L, et al. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015;150:1484–92; discussion 1492.

[42] Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects. Oncotarget. 2016;7:62619–26.

[43] Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37:2235–45.

[44] Zhang Y, Hu X, Liu D, et al. Effectiveness of neoadjuvant chemotherapy on the survival outcomes of patients with resectable non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Surg Oncol. 2021;38:101590.

[45] Qui B, Men Y, Wang J, et al. Dosimetry, efficacy, safety, and cost-effectiveness of proton therapy for non-small cell lung cancer. Cancers. 2021;13:4545.

[46] Rodak O, Peris-Díaz MD, Olbromski M, et al. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers. 2021;13:4705.